Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial

Anticancer Res. 2013 Jun;33(6):2785-9.

Abstract

Aim: To report the acute toxicity of a hypofractionated regimen of intensity-modulated radiotherapy with simultaneous integrated boost (SIB-IMRT) to the pelvic nodes and the prostatic bed after radical prostatectomy.

Patients and methods: Patients with prostate adenocarcinoma at high risk of relapse after radical prostatectomy or with biochemical relapse were deemed eligible for study. SIB-IMRT was prescribed to the whole pelvis (45-Gy delivered in 1.8-Gy fractions) and the prostatic bed [62.5 Gy, 2.5-Gy fractions, Equivalent Dose in 2-Gy fraction (EQD2)=68.75 Gy, α/β=3]. Acute toxicity was recorded and graded according to Radiation Therapy Oncology Group (RTOG) criteria.

Results: Forty-nine patients were enrolled. No cases of grade ≥ 3 acute toxicity were recorded. Grade 2 acute genitourinary and gastrointestinal toxicity was observed in 9.6% and 29.7% of patients, respectively.

Conclusion: After radical prostatectomy, hypofractionated high-dose SIB-IMRT enables for reduction of the overall treatment time, with an acute toxicity profile which compares favourably with that of conventionally fractionated high-dose three-dimensional conformal radiotherapy (3D-CRT).

Keywords: Post-operative radiotherapy; SIB-IMRT; hypofractionation; phase II trial; prostate cancer.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Adenocarcinoma / radiotherapy*
  • Adenocarcinoma / surgery*
  • Aged
  • Combined Modality Therapy
  • Dose Fractionation, Radiation
  • Gastrointestinal Diseases
  • Humans
  • Male
  • Middle Aged
  • Prostatectomy*
  • Prostatic Neoplasms / radiotherapy*
  • Prostatic Neoplasms / surgery*
  • Radiation Injuries
  • Radiotherapy, Intensity-Modulated* / adverse effects